Table 2 Drugs for which currently recommended anti-malarial regimens maybe inadequate in important patient groups.
From: Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance
Drug | Dose | Patient group | Comment |
|---|---|---|---|
Dihydroartemisinin-piperaquine | 2.5/20 mg/kg/day for 3 days | All | The current adult DHA dose of 120 mg may be too low. The piperaquine dose may be too low in children |
Sulphadoxine -pyrimethamine | 1.25/25 mg/kg | Children, pregnant women | Higher doses have not been evaluated |
Atovaquone-proguanil | 8/20 mg/kg for 3 days | Pregnant women | Higher doses have not been evaluated |
Artemether-lumefantrine | 1.5/9 mg/kg for 3 days with fat | Pregnant women Hyperparasitaemic patients | Lumefantrine absorption is dose limited. Longer courses have not been evaluated in pregnancy |
Artesunate | Oral 2 mg/kg/day 7 days 2.4 mg/kg i.v. | Pregnant women | Higher doses have not been evaluated in pregnancy |
Artemether | Oral 2 mg/kg/day 7 days 3.2 mg/kg i.m. | Pregnant women | Higher doses have not been evaluated in pregnancy |